<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hitt Nichols, Emma</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Cortes, Jorge</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Dasatinib Outcomes Maintained Over 5 Years</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">19-20</style></pages><abstract><style  face="normal" font="default" size="100%">A new analysis from the DASISION trial showed that long-term treatment with dasatinib, compared with imatinib, in patients with treatment-naïve, chronic phase myeloid leukemia improved rates of major molecular response and molecular response, but not overall survival or progression-free survival, in the patients who completed 5 years of follow-up, without new safety signals.</style></abstract><number><style face="normal" font="default" size="100%">55</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>